Abstract:Tuberculosis is reported to be associated with the severity and mortality amongst patients with coronavirus disease 2019 (COVID-19).1 However, the reported prevalence of comorbid tuberculosis amongst COVID-19 patients varied greatly across the published studies. For example, the low prevalence of comorbid tuberculosis amongst COVID-19 patients was reported in Tian et al's study (0.4%)2 and Yan et al's study (0.2%)3 and the relatively high prevalence of comorbid tuberculosis amongst COVID-19 patients was reported in Hu et al's study (4.5%)4 and Zhang et al's study (9.0%).5 Therefore, it is needed to quantitatively estimate the pooled prevalence of comorbid tuberculosis amongst COVID-19 patients using a meta-analysis. A systematic literature search was conducted independently by two investigators in PubMed, Web of Science, EMBASE, Springer, Elsevier-ScienceDirect, Wiley Online Library, Scopus and Cochrane Library databases to select all eligible studies which were published from 1 January 2020 to 31 August 2021. The following keywords were used: "prevalence" or "incidence" or "rate" or "characteristics" and "tuberculosis" and "COVID-19" or "SARS-CoV-2" or "2019-nCoV" or "severe acute respiratory syndrome coronavirus 2" or "coronavirus disease 2019" or "2019 novel coronavirus". All peer-reviewed papers which were published in the English language were eligibly included if they provided the incidence rate of comorbid tuberculosis amongst COVID-19 patients. Accordingly, we excluded case reports, review articles, duplicate publications, errata, comments and preprints. Reference lists of the retrieved articles were also screened to identify additional studies. This rapid systematic review and meta-analysis was performed following the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA).6 The pooled prevalence of comorbid tuberculosis amongst COVID-19 patients was estimated using a random effects meta-analysis model.7, 8 The statistical heterogeneity across studies was assessed by I2 statistic and Cochrane Q test.9, 10 The risk of publication bias was evaluated by Begg's rank correlation test.11, 12 All statistical analyses were carried out using the package "meta" on R version 3.6.3 (R Foundation for Statistical Computing). A two-tailed P value <.05 was regarded statistically significant. A total of 114 eligible studies2-5, 13-122 with 405 596 COVID-19 patients were included in this meta-analysis. Amongst the included studies, 77 studies2-5, 13-85 were reported in Asia, 15 studies90-100 were conducted in Africa, nine studies101-109 were conducted in South America, five studies110-114 were performed in North America, seven studies115-121 were conducted in Europe and one study122 was from multicountries. The baseline characteristics of the included studies are summarised in Table 1. Overall, our findings demonstrated that the prevalence of comorbid tuberculosis amongst COVID-19 patients in this pooled meta-analysis was 1.6% with 95% confidence interval (CI): 1.3%–1.9% (Figure 1). The regional tuberculosis prevalence in COVID-19 patients was estimated as follows: Africa (4.1%, 95% CI: 0.0%–5.8%), Asia (1.1%, 95% CI: 0.9%–1.3%), South America (0.5%, 95% CI: 0.0%–1.0%), Europe (0.4%, 95% CI: 0.0%–0.6%) and North America (0.2%, 95% CI: 0.0%–0.4%), which revealed great variability in the prevalence of comorbid tuberculosis amongst COVID-19 patients in different regions. Begg's test revealed that there was potential publication bias (P = .0017). In conclusion, our findings demonstrated that the prevalence of comorbid tuberculosis amongst COVID-19 patients was 1.6%, which varied greatly in different regions. We would like to thank Wenwei Xiao, Xuan Liang, Peihua Zhang, Yang Li and Jian Wu (All are from Department of Epidemiology, School of Public Health, Zhengzhou University) for their kind help in searching articles and collecting data. The authors declare that they have no any potential conflict of interest regarding this submitted manuscript. Yadong Wang and Haiyan Yang designed the study. Jie Xu, Ying Wang, Hongjie Hou and Li Shi performed literature search and data extraction. Jie Xu and Yadong Wang performed data analysis. Yadong Wang and Haiyan Yang wrote and reviewed the manuscript. All the authors approved the final manuscript. The data that support the findings of this study are included in this article and available from the corresponding author upon reasonable request.

The impact of COVID-19 pandemic on reported tuberculosis incidence and mortality in China: An interrupted time series analysis

The Impact of COVID-19 Pandemic on Reported Notifiable Infectious Diseases in China: an Interrupted Time Series Analysis

Impact of COVID-19 Pandemic on Pre-Treatment Delays, Detection, and Clinical Characteristics of Tuberculosis Patients in Ningxia Hui Autonomous Region, China

Impact of the COVID-19 Pandemic on the Incidence of Notifiable Infectious Diseases in China Based on SARIMA Models Between 2013 and 2021

Interrupted time series analysis using the ARIMA model of the impact of COVID-19 on the incidence rate of notifiable communicable diseases in China

Sex disparities of the effect of the COVID-19 pandemic on mortality among patients living with tuberculosis in the United States

The Impact of COVID-19 Lockdown on Cases of and Deaths from AIDS, Gonorrhea, Syphilis, Hepatitis B, and Hepatitis C: Interrupted Time Series Analysis.

Changes in Incidence of Notifiable Infectious Diseases in China Under the Prevention and Control Measures of COVID-19

Changes in the incidence, clinical features and outcomes of tuberculosis during COVID-19 pandemic

Epidemic Trends of Tuberculosis in China from 1990 to 2017: Evidence from the Global Burden of Disease Study.

Effects of the COVID-19 pandemic on TB outcomes in the United States: a Bayesian analysis

The impact of the COVID-19 pandemic on the incidence and mortality of zoonotic diseases in China

Estimating and Forecasting the Impact of COVID-19 on Infectious Disease Incidence in Mainland China: A Retrospective Analysis and Projections for a Post-Pandemic Future

Analysis on time delay of tuberculosis among adolescents and young adults in Eastern China

The Epidemic of Sexually Transmitted Diseases Under the Influence of COVID-19 in China

Prevalence of Comorbid Tuberculosis Amongst COVID‐19 Patients: A Rapid Review and Meta‐analysis

COVID-19 and Tuberculosis Coinfection: An Overview of Case Reports/Case Series and Meta-Analysis

The impact of the COVID-19 pandemic on health services utilization in China: Time-series analyses for 2016–2020

Temporal shifts in 24 notifiable infectious diseases in China before and during the COVID-19 pandemic

The Effect of the SARS-CoV-2 Pandemic on Health Services Utilization in China: Time-Series Analyses for 2016-2020

Tuberculosis healthcare service disruptions during the COVID-19 pandemic in Brazil, India and South Africa: A model-based analysis of country-level data